Drugs / GW273225
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00501865 | Aug → Oct 2007 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00483535 | Mar → Nov 2007 | bipolar disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00567424 | Jul 2006 → Mar 2008 | epilepsy | GlaxoSmithKline | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW273225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00483535 ↗ |
| Route | Oral | “Subjects will be randomized to sequence AB, where A represents fasted state and B represents fed state. Subjects will be administered a single oral dose of GW273225 50...” NCT00501865 ↗ |